Neurocrine Biosciences(NBIX.US) Officer Sells US$38,370.15 in Common Stock
$Neurocrine Biosciences(NBIX.US)$ Officer Delaet Ingrid sold 273 shares of common stock on May 6, 2024 at an average price of $140.55 for a total value of $38,370.15.Source: Announcement What is state
Neurocrine Biosciences To Begin Initiation Of Phase 1 Clinical Study Evaluating Effects Of NBI-1117567 In Healthy Adults
Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of
Express News | Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of Nbi-1117567 in Healthy Adults
Neurocrine Biosciences To Present Phase 3 Baseline Characteristics Data From The CAHtalyst Program Of Crinecerfont In CAH, And Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH Studies At ECE 2024
CAHtalyst Pediatric and CAHtalyst Adult Baseline Characteristics Data in Congenital Adrenal HyperplasiaPhase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone (Chronocort/Efmody) in
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las Vegas. Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during...
Neurocrine Is Maintained at Neutral by Citigroup
Neurocrine Is Maintained at Neutral by Citigroup
Express News | Citigroup Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $150
Express News | Neurocrine Biosciences Inc : Citigroup Raises Target Price to $150 From $140
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $170
Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $164 to $170.
Neurocrine Is Maintained at Overweight by Barclays
Neurocrine Is Maintained at Overweight by Barclays
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating
Neurocrine Biosciences (NBIX) has an average outperform rating and a price target range of $111 to $200, according to analysts polled by Capital IQ. Price: 143.01, Change: -0.02, Percent Change: -0.0
Neurocrine Price Target Raised to $138.00/Share From $129.00 by BMO Capital
Neurocrine Price Target Raised to $138.00/Share From $129.00 by BMO Capital
Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)
Express News | Neurocrine Biosciences : Oppenheimer Raises Target Price to $216 From $200
Neurocrine Biosciences: A Balanced Hold Rating Amidst Revenue Growth and Rising Expenses
Neurocrine Is Maintained at Buy by HC Wainwright & Co.
Neurocrine Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Raises Price Target to $160
Express News | Neurocrine Biosciences Inc. : Barclays Raises Target Price to $169 From $150
Buy Rating Affirmed for Neurocrine Biosciences on Strong Performance and Promising Pipeline
No Data